Plozasiran is not yet approved for commercial use in the U.S., but, as Healio previously reported, it received a breakthrough therapy designation from the FDA, and Arrowhead plans to file an ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients ...

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Moving Plozasiran Ahead in CVOT Trial On June 25, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) held a ...

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

"Plozasiran produced significant reductions in triglyceride levels below the threshold associated with elevated risk for pancreatitis," concluded lead investigator Daniel Gaudet, MD, PhD ...

Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of Apolipoprotein C-III (APOC3) which is a component ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

A rrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for plozasiran for the treatment for familial chylomicronemia syndrome (FCS). In FCS, mutations in the ...

Arrowhead Pharmaceuticals, Inc. today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed ...